Intercell Receives Manufacturer's Licence for Future Commercial Manufacturing of its Vaccine Against Japanese Encephalitis
Intercell receives Manufacturer's Licence for its site in Livingston, Scotland
The Manufacturer's Licence is required to support the Marketing Authorization Application (MAA) process in Europe which is being coordinated by the European Medicines Agency (EMEA) and represents the basis for future product release and export to the US.
The issuance of the Commercial Manufacturer's Licence is a key achievement on Intercell´s path to bringing our new investigational Japanese Encephalitis vaccine onto the market and should allow us to produce a sufficient launch stock for product approvals in the respective locations, states Gerd Zettlmeissl, Intercell´s Chief Executive Officer.
Intercell expects the preapproval inspection by the US FDA (Food and Drug Administration) in support of the US licensure process within the forthcoming months.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.